Clinical trials: Mesenchymal Stromal Cells
Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater…
- Conditions
- Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy
- Trial name
- NCT07265349
- Testing
- Mesenchymal stem cells(HucMSCs), CABG
- Where
- 4 sites in China
- Volunteers
- 51 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Degenerative Disc Disease, Intervertebral Disc Disease
Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)
In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC), obtained from bone marrow of healthy donors, for treatment of Degenerative Disc Disease (DDD).
- Conditions
- Degenerative Disc Disease, Intervertebral Disc Disease, Low Back Pain
- Trial name
- Disc_allo (NCT01860417)
- Testing
- Allogenic Mesenchymal Stromal Cells, Mepivacaine
- Where
- 2 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Red de Terapia Celular
Musculoskeletal Injury
A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration
The goal of this ongoing open-label, single-arm, phase I/IIa study in patients is designed to assess the safety of human allogeneic BM-derived MSCs product StromaForte for musculoskeletal injury or/and degeneration.
- Trial name
- NCT06074783
- Testing
- Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)
- Where
- The Bahamas
- Volunteers
- 30 people
- Sponsor
- Cellcolabs Clinical LTD.
Acute Ischemic Stroke
A Study of B2065 in Patients With Acute Ischemic Stroke
The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke.
- Trial name
- NCT07371624
- Testing
- B2065
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease.
- Trial name
- AMSC-ALS-001 (NCT03828123)
- Testing
- Suspension of human autologous MSC 3P in 1.5 ml
- Volunteers
- 26 people
- Sponsor
- Bioinova, s.r.o.
Knee Osteoarthritis
A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA
This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It is a dose-escalating, open label study in adult KOA subjects.
- Trial name
- NCR100 (NCT06049342)
- Testing
- NCR100 injection
- Volunteers
- 12 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Steroid-refractory Acute Graft-versus-host Disease
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
The primary purpose of this trial is to demonstrate the superiority of MC0518 compared to the first used best available therapy (BAT) with respect to overall response rate (ORR) at Day 28 and/or overall survival (OS) until Visit…
- Trial name
- IDUNN (NCT04629833)
- Testing
- MC0518, BAT
- Where
- 42 sites in France, Germany and 3 more
- Volunteers
- 210 people
- Sponsor
- medac GmbH
Interstitial Lung Disease (ILD)
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease
The target of this trial is to evaluate the safety, tolerability and preliminary efficacy of NCR101 in the treatment of subjects with interstitial lung disease.
- Trial name
- NCT06825169
- Testing
- NCR101 injection
- Volunteers
- 30 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Acute Ischemic Stroke, AIS
A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke
Study Methods: The trial consists of two phases, both including a placebo control. Phase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set.
- Trial name
- NCT07628933
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 35 people
- Sponsor
- BOE Technology Group Co., Ltd.
Hereditary Ataxia
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia
The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements.
- Trial name
- NCT01360164
- Testing
- human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Venous Leg Ulcer
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.
- Trial name
- NCT06489028
- Testing
- allo-APZ2-CVU
- Where
- 15 sites in United States, Austria and 10 more
- Volunteers
- 250 people
- Sponsor
- RHEACELL GmbH & Co. KG
Osteoarthritis
Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.
This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction (AD-SVF) implantation performed intra-articularly to affected joints.
- Trial name
- NCT01739504
- Testing
- Liposuction with Local Anesthesia, Intra articular infusion of AD-SVF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ageless Regenerative Institute
Decompensated Hepatitis B Cirrhosis
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis
Phase I (Single Administration, Randomized, Double-blind, Dose Escalation)Primary Objective: To evaluate the safety and tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis…
- Trial name
- HBV-DC (NCT07413549)
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Beijing Tuohua Weiye Biotechnology Co., Ltd.
Liver Cirrhosis
Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis
Although liver transplantation provide a option to cure patients suffering with decompensated liver cirrhosis this condition, lack of donors, postoperative complications, especially rejection, and high cost limit its application.
- Trial name
- NCT01342250
- Testing
- conventional therapy plus low dose hUC-MSCs treatment, conventional therapy plus medium dose hUC-MSCs treatment, conventional therapy plus high dose hUC-MSCs treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Knee Osteoarthritis
A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）
This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It contains two parts dose-escalating, and blind random study in adult KOA subjects.
- Trial name
- NCT06741098
- Testing
- NCR100, 0.9% Normal saline
- Volunteers
- 162 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Grade B aGVHD, Grade C aGVHD
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to…
- Conditions
- Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
- Trial name
- NCT02336230
- Testing
- remestemcel-L
- Where
- 20 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mesoblast, Inc.
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy…
- Trial name
- NCT05962762
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
SLE, Lupus
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to answer are: 1.
- Conditions
- SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus
- Trial name
- NCT06737380
- Testing
- Physical examination, Electrocardiogram, SF-36 questionnaire
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- LiveKidney.Bio
COVID-19 Acute Respiratory Distress Syndrome, Influenza A
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Influenza A, Metapneumovirus Pneumonia, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT04896853
- Testing
- ProTrans®
- Where
- Sweden
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NextCell Pharma Ab